BRPI0914657A2 - piridin-2-onae piridazin-3-onas substituídas - Google Patents

piridin-2-onae piridazin-3-onas substituídas

Info

Publication number: BRPI0914657A2
Authority: BR; Brazil
Prior art keywords: pyridazin; ones; substituted pyridin; pyridin; substituted
Prior art date: 2008-06-24

Application number

BRPI0914657A

Other languages

English (en)

Inventor

E Loe Bradley

mcintosh Joel

Soth Michael

James Dewdney Nolan

K Kondru Rama

d owens Timothy

Lou Yan

Original Assignee

F Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-24

Filing date

2009-06-15

Publication date

2019-09-24

2009-06-15 Application filed by F Hoffmann La Roche filed Critical F Hoffmann La Roche

2019-09-24 Publication of BRPI0914657A2 publication Critical patent/BRPI0914657A2/pt

Links

PAXBXCBVFOOXPP-UHFFFAOYSA-N 1H-pyridazin-6-one 1H-pyridin-2-one Chemical class N=1NC(C=CC1)=O.N1C(C=CC=C1)=O PAXBXCBVFOOXPP-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)

BRPI0914657A 2008-06-24 2009-06-15 piridin-2-onae piridazin-3-onas substituídas BRPI0914657A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7527708P	2008-06-24	2008-06-24
PCT/EP2009/057320 WO2009156284A1 (en)	2008-06-24	2009-06-15	Novel substituted pyridin-2-ones and pyridazin-3-ones

Publications (1)

Publication Number	Publication Date
BRPI0914657A2 true BRPI0914657A2 (pt)	2019-09-24

Family

ID=40972952

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0914657A BRPI0914657A2 (pt)	2008-06-24	2009-06-15	piridin-2-onae piridazin-3-onas substituídas

Country Status (25)

Country	Link
US (4)	US7902194B2 (pt)
EP (1)	EP2297142B1 (pt)
JP (1)	JP5536049B2 (pt)
KR (1)	KR101299867B1 (pt)
CN (3)	CN103709148B (pt)
AR (1)	AR072272A1 (pt)
AU (1)	AU2009264400B2 (pt)
BR (1)	BRPI0914657A2 (pt)
CA (1)	CA2728016C (pt)
CL (1)	CL2010001483A1 (pt)
CO (1)	CO6382183A2 (pt)
CR (1)	CR11815A (pt)
EC (1)	ECSP10010709A (pt)
ES (1)	ES2552320T3 (pt)
IL (1)	IL209141A0 (pt)
MA (1)	MA32487B1 (pt)
MX (1)	MX2010013191A (pt)
NZ (2)	NZ588819A (pt)
PE (1)	PE20100851A1 (pt)
PH (2)	PH12012502374A1 (pt)
RU (1)	RU2500680C2 (pt)
TW (1)	TWI396537B (pt)
UA (1)	UA103327C2 (pt)
WO (1)	WO2009156284A1 (pt)
ZA (1)	ZA201007816B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200900396A (en) *	2007-04-10	2009-01-01	Kudos Pharm Ltd	Phthalazinone derivatives
PE20110164A1 (es) *	2008-07-02	2011-03-28	Hoffmann La Roche	Nuevas fenilpirazinonas como inhibidores de quinasa
US8299077B2 (en) *	2009-03-02	2012-10-30	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase
WO2010122038A1 (en) *	2009-04-24	2010-10-28	F. Hoffmann-La Roche Ag	Inhibitors of bruton's tyrosine kinase
EP2566869B1 (en)	2010-05-07	2016-03-02	Gilead Connecticut, Inc.	Pyridone and aza-pyridone compounds and methods of use
AR082590A1 (es)	2010-08-12	2012-12-19	Hoffmann La Roche	Inhibidores de la tirosina-quinasa de bruton
US8975260B2 (en)	2010-09-01	2015-03-10	Genetech, Inc	Pyridazinones, method of making, and method of use thereof
CA2841801A1 (en)	2011-08-17	2013-02-21	F.Hoffmann-La Roche Ag	Inhibitors of bruton's tyrosine kinase
UA111756C2 (uk)	2011-11-03	2016-06-10	Ф. Хоффманн-Ля Рош Аг	Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
MX2014005285A (es) *	2011-11-03	2014-05-30	Hoffmann La Roche	Compuestos biciclicos de piperazina.
EP2773639B1 (en)	2011-11-03	2017-04-26	F. Hoffmann-La Roche AG	Alkylated piperazine compounds as inhibitors of btk activity
MX2014005282A (es) *	2011-11-03	2014-05-30	Hoffmann La Roche	Compuestos de 8-fluoroftalazin-1 (2h) -ona.
JP5832664B2 (ja)	2011-12-09	2015-12-16	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ブルトン型チロシンキナーゼの阻害剤
US9365566B2 (en)	2012-03-27	2016-06-14	Takeda Pharmaceutical Company Limited	Cinnoline derivatives
CN104704129A (zh)	2012-07-24	2015-06-10	药品循环公司	与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
SG11201500499TA (en)	2012-08-10	2015-03-30	Boehringer Ingelheim Int	Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
WO2014040965A1 (en) *	2012-09-13	2014-03-20	F. Hoffmann-La Roche Ag	Inhibitors of bruton's tyrosine kinase
JP6088063B2 (ja) *	2012-11-16	2017-03-01	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ブルトン型チロシンキナーゼの阻害剤
RU2618529C2 (ru) *	2013-03-05	2017-05-04	Ф. Хоффманн-Ля Рош Аг	Ингибиторы тирозинкиназы брутона
JO3377B1 (ar)	2013-03-11	2019-03-13	Takeda Pharmaceuticals Co	مشتقات بيريدينيل وبيريدينيل مندمج
CN104177338B (zh) *	2013-05-22	2018-04-03	南京勇山生物科技有限公司	一类布鲁顿激酶抑制剂
WO2015000949A1 (en) *	2013-07-03	2015-01-08	F. Hoffmann-La Roche Ag	Heteroaryl pyridone and aza-pyridone amide compounds
CN112472699A (zh)	2013-07-26	2021-03-12	种族肿瘤学公司	改善比生群及衍生物的治疗益处的组合方法
KR101810798B1 (ko)	2013-07-30	2017-12-19	질레드 코네티컷 인코포레이티드	Ｓｙｋ 억제제의 다형체
PE20160605A1 (es)	2013-07-30	2016-07-20	Gilead Connecticut Inc	Formulaciones de inhibidores de la syk
WO2015082583A1 (en)	2013-12-05	2015-06-11	F. Hoffmann-La Roche Ag	Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
WO2015086642A1 (en) *	2013-12-13	2015-06-18	F. Hoffmann-La Roche Ag	Inhibitors of bruton's tyrosine kinase
TWI735853B (zh)	2013-12-23	2021-08-11	美商克洛諾斯生技有限公司	脾酪胺酸激酶抑制劑
TW201702218A (zh)	2014-12-12	2017-01-16	美國杰克森實驗室	關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US10570118B2 (en) *	2016-01-13	2020-02-25	Boehringer Ingelheim International Gmbh	Isoquinolones as BTK inhibitors
DK3436447T3 (da)	2016-03-31	2021-09-13	Takeda Pharmaceuticals Co	Isoquinolinyl-triazolon-komplekser
IL292938A (en)	2016-09-19	2022-07-01	Mei Pharma Inc	Combined treatment
EP3672974A1 (en)	2017-08-25	2020-07-01	Gilead Sciences, Inc.	Polymorphs of syk inhibitors
WO2019126731A1 (en)	2017-12-22	2019-06-27	Petra Pharma Corporation	Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2020140054A1 (en)	2018-12-28	2020-07-02	Spv Therapeutics Inc.	Cyclin-dependent kinase inhibitors
US11339168B2 (en)	2019-02-22	2022-05-24	Kronos Bio, Inc.	Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
EA202192575A1 (ru)	2019-03-21	2022-01-14	Онксео	Соединения dbait в сочетании с ингибиторами киназ для лечения рака
TW202112767A (zh)	2019-06-17	2021-04-01	美商佩特拉製藥公司	作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN114761006A (zh)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1070056T1 (en) *	1998-03-14	2004-12-31	Altana Pharma Ag	Phthalazinone pde iii/iv inhibitors
AU5179000A (en) *	1999-06-03	2000-12-28	Basf Aktiengesellschaft	Benzothiazinone and benzoxazinone compounds
CA2387351C (en) *	1999-10-19	2009-09-08	Merck & Co., Inc.	Indole derivatives as tyrosine kinase inhibitors
AU2003270489A1 (en)	2002-09-09	2004-03-29	Cellular Genomics, Inc.	6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
US7405295B2 (en)	2003-06-04	2008-07-29	Cgi Pharmaceuticals, Inc.	Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
MX2007011041A (es) *	2005-03-10	2008-02-22	Cgi Pharmaceuticals Inc	Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
WO2006124731A2 (en)	2005-05-12	2006-11-23	Irm Llc	Compounds and compositions as protein kinase inhibitors
WO2007021795A2 (en)	2005-08-09	2007-02-22	Irm Llc	Compounds and compositions as protein kinase inhibitors
JP5112317B2 (ja)	2005-08-29	2013-01-09	バーテックスファーマシューティカルズインコーポレイテッド	非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン
ATE548363T1 (de) *	2005-08-29	2012-03-15	Vertex Pharma	3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
EP1919906B1 (en)	2005-08-29	2011-10-12	Vertex Pharmaceuticals Incorporated	3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
CN101405001A (zh) *	2006-03-20	2009-04-08	霍夫曼-拉罗奇有限公司	抑制btk和syk蛋白质激酶的方法
MX2008014618A (es) *	2006-05-15	2008-11-28	Irm Llc	Composiciones y metodos para inhibidores de cinasas del receptor fgf.
US7838523B2 (en) *	2006-09-11	2010-11-23	Cgi Pharmaceuticals, Inc.	Certain substituted amides, method of making, and method of use thereof
AR063706A1 (es)	2006-09-11	2009-02-11	Cgi Pharmaceuticals Inc	Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
WO2008033858A2 (en)	2006-09-11	2008-03-20	Cgi Pharmaceuticals, Inc.	Kinase inhibitors, and methods of using and identifying kinase inhibitors
PE20081370A1 (es)	2006-09-11	2008-11-28	Cgi Pharmaceuticals Inc	Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
CL2008002793A1 (es)	2007-09-20	2009-09-04	Cgi Pharmaceuticals Inc	Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CN101835755B (zh) *	2007-10-23	2013-12-11	霍夫曼-拉罗奇有限公司	激酶抑制剂
JP5643105B2 (ja)	2007-12-14	2014-12-17	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	新規イミダゾ［１，２−ａ］ピリジン及びイミダゾ［１，２−ｂ］ピリダジン誘導体
PL2242749T3 (pl)	2008-02-05	2013-09-30	Hoffmann La Roche	Nowe pirydynony i pirydazynony
US7683064B2 (en)	2008-02-05	2010-03-23	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase

2009
- 2009-06-15 PH PH1/2012/502374A patent/PH12012502374A1/en unknown
- 2009-06-15 ES ES09769133.1T patent/ES2552320T3/es active Active
- 2009-06-15 UA UAA201100578A patent/UA103327C2/ru unknown
- 2009-06-15 WO PCT/EP2009/057320 patent/WO2009156284A1/en not_active Ceased
- 2009-06-15 CN CN201310740898.1A patent/CN103709148B/zh not_active Expired - Fee Related
- 2009-06-15 PE PE2010001046A patent/PE20100851A1/es not_active Application Discontinuation
- 2009-06-15 KR KR1020107029040A patent/KR101299867B1/ko not_active Expired - Fee Related
- 2009-06-15 BR BRPI0914657A patent/BRPI0914657A2/pt not_active IP Right Cessation
- 2009-06-15 CN CN200980123734.6A patent/CN102066366B/zh not_active Expired - Fee Related
- 2009-06-15 JP JP2011514004A patent/JP5536049B2/ja not_active Expired - Fee Related
- 2009-06-15 RU RU2011101774/04A patent/RU2500680C2/ru not_active IP Right Cessation
- 2009-06-15 AU AU2009264400A patent/AU2009264400B2/en not_active Expired - Fee Related
- 2009-06-15 NZ NZ588819A patent/NZ588819A/xx not_active IP Right Cessation
- 2009-06-15 CA CA2728016A patent/CA2728016C/en not_active Expired - Fee Related
- 2009-06-15 EP EP09769133.1A patent/EP2297142B1/en active Active
- 2009-06-15 NZ NZ601700A patent/NZ601700A/xx not_active IP Right Cessation
- 2009-06-15 MX MX2010013191A patent/MX2010013191A/es active IP Right Grant
- 2009-06-15 CN CN201310343743.4A patent/CN103408533B/zh not_active Expired - Fee Related
- 2009-06-15 PH PH1/2012/502375A patent/PH12012502375A1/en unknown
- 2009-06-22 AR ARP090102276A patent/AR072272A1/es not_active Application Discontinuation
- 2009-06-23 TW TW098121074A patent/TWI396537B/zh not_active IP Right Cessation
- 2009-06-24 US US12/456,911 patent/US7902194B2/en not_active Expired - Fee Related
2010
- 2010-10-25 CO CO10132213A patent/CO6382183A2/es active IP Right Grant
- 2010-11-01 ZA ZA2010/07816A patent/ZA201007816B/en unknown
- 2010-11-04 IL IL209141A patent/IL209141A0/en unknown
- 2010-11-25 CR CR11815A patent/CR11815A/es not_active Application Discontinuation
- 2010-12-20 CL CL2010001483A patent/CL2010001483A1/es unknown
- 2010-12-23 EC EC2010010709A patent/ECSP10010709A/es unknown
2011
- 2011-01-10 US US12/987,187 patent/US8124604B2/en not_active Expired - Fee Related
- 2011-01-18 MA MA33534A patent/MA32487B1/fr unknown
2012
- 2012-01-26 US US13/358,557 patent/US8618098B2/en not_active Expired - Fee Related
2013
- 2013-09-11 US US14/024,354 patent/US8822457B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
RU2500680C2 (ru)	2013-12-10
US20110105479A1 (en)	2011-05-05
CN103408533A (zh)	2013-11-27
US8124604B2 (en)	2012-02-28
ES2552320T3 (es)	2015-11-27
CR11815A (es)	2011-01-10
NZ588819A (en)	2012-08-31
IL209141A0 (en)	2011-01-31
CN103709148A (zh)	2014-04-09
CN102066366A (zh)	2011-05-18
US8822457B2 (en)	2014-09-02
PH12012502375A1 (en)	2013-06-17
RU2011101774A (ru)	2012-07-27
CO6382183A2 (es)	2012-02-15
KR101299867B1 (ko)	2013-08-23
US20120129845A1 (en)	2012-05-24
CA2728016C (en)	2017-02-28
US7902194B2 (en)	2011-03-08
JP2011524404A (ja)	2011-09-01
US20140194413A1 (en)	2014-07-10
HK1152940A1 (en)	2012-03-16
ZA201007816B (en)	2011-08-31
CN103408533B (zh)	2015-08-26
CN102066366B (zh)	2014-04-16
TWI396537B (zh)	2013-05-21
CN103709148B (zh)	2015-10-21
US20090318448A1 (en)	2009-12-24
NZ601700A (en)	2013-02-22
EP2297142A1 (en)	2011-03-23
CA2728016A1 (en)	2009-12-30
HK1196358A1 (en)	2014-12-12
KR20110011706A (ko)	2011-02-08
MA32487B1 (fr)	2011-07-03
EP2297142B1 (en)	2015-10-14
AR072272A1 (es)	2010-08-18
JP5536049B2 (ja)	2014-07-02
AU2009264400A1 (en)	2009-12-30
UA103327C2 (en)	2013-10-10
WO2009156284A1 (en)	2009-12-30
MX2010013191A (es)	2010-12-17
TW201002683A (en)	2010-01-16
US8618098B2 (en)	2013-12-31
AU2009264400B2 (en)	2014-05-01
PH12012502374A1 (en)	2014-11-12
PE20100851A1 (es)	2011-01-31
CL2010001483A1 (es)	2011-05-13
ECSP10010709A (es)	2011-01-31

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
FIC20240020I1 (fi)	2024-06-07	Atetsolitsumabi
NL301046I2 (nl)	2020-07-29	Siponimod
NL300965I1 (nl)	2019-02-06	Patisiran
NL300961I2 (nl)	2019-01-15	Erenumab
BRPI0914657A2 (pt)	2019-09-24	piridin-2-onae piridazin-3-onas substituídas
DK2376490T3 (da)	2013-04-15	Imidazopyridinforbindelser
DK2340021T3 (da)	2012-12-10	Substituerede pyrrolidin-2-carboxamider
EP2351549A4 (en)	2015-06-24	INTERCONNECTS
BRPI0907376A2 (pt)	2015-07-14	Fotobiorretador
BRPI0914649A2 (pt)	2015-07-07	Piprazolo-quinazolinas
FI20086158A0 (fi)	2008-12-03	Imidatsopyridiinijohdannaiset
FIU20080329U0 (fi)	2008-10-20	Kanylointisimulantti
NL300884I2 (nl)	2017-08-31	Ozenoxacin
BRPI0911625A2 (pt)	2015-08-04	Métodos
BRPI0907522A2 (pt)	2019-09-24	biarlamidas
DE112009000183A5 (de)	2011-02-03	Sicherheitsvorreiber
EP2339366A4 (en)	2013-01-30	DEVICE FOR OPTICAL DISTANCE MEASUREMENT
BRPI0909634A2 (pt)	2015-09-22	2-aminoquinolinas
DE112009001946A5 (de)	2011-07-14	Mobelauszugsführung
BRPI0909637A2 (pt)	2015-09-22	2-aminoquinolinas
BRPI0907863A2 (pt)	2019-09-24	pirrolopirimidinacarboxamidas
AT507449A3 (de)	2010-11-15	Dämmstoffbefestiger
NO20083166L (no)	2010-01-18	Fortoyningsarrangement
DE502008003019D1 (de)	2011-05-12	Einschraubverschraubung
ES1067763Y (es)	2008-09-16	Dendrometro